Survival Significance of Molecular Pathology and Genetic Variation in Brain Gliomas

Survival Significance and Clinical Characteristics of Molecular Pathology and Genetic Variation in Brain Gliomas

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04216537

Enrollment

3000

Registered

2020-01-02

Start date

2018-01-01

Completion date

2025-06-01

Last updated

2021-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genetic Change, Glioma, Molecular Sequence Variation

Keywords

Survival, Subgroup

Brief summary

This study aims to collect clinical, radiological, pathological, molecular and genetic data including detailed clinical parameters, MR and histopathology images, molecular pathology and genetic data. This study seeks to find the prognostic and clinical significance based on molecular and genetic biomarkers/subgroups of gliomas.

Detailed description

Precise classification based on molecular and genetic biomarkers/subgroups for gliomas is challenging. This study aims to collect clinical, radiological, pathological, molecular and genetic data including detailed clinical parameters, MR and histopathology images, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and genetic data (Whole exome sequencing, RNA sequencing, proteomics, etc). This study seeks to find the prognostic and clinical significance based on molecular and genetic biomarkers/subgroups of gliomas.

Interventions

DIAGNOSTIC_TESTGlioma groups based on molecular pathology or genetic variation

Patients with newly diagnosed glioma that receive tumor resection

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

1 Years to 95 Years

Healthy volunteers

Inclusion criteria

* Patients must have radiologically and histologically confirmed diagnosis of primary glioma * Life expectancy of greater than 3 months * Must receive tumor resection * Must have sufficient fresh frozen tissues for NGS * Signed informed consent

Exclusion criteria

* No gliomas * No sufficient amount of tumor tissues for detection of molecular pathology * Patients who are pregnant or breast feeding * Patients who are suffered from severe systematic malfunctions * Do not have sufficient fresh frozen tissues for NGS

Design outcomes

Primary

Measure	Time frame	Description
Overall Survival (OS)	From enrollment to death of patients. Estimated about 5 years.	The length of time from enrollment until the time of death (OS, overall survival)

Countries

China

Contacts

Primary ContactZhenyu Zhang, Dr.

fcczhangzy1@zzu.edu.cn+86 17839973727

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026